Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.

ABSTRACT:

Objective

To review the clinical pharmacology, efficacy, and safety of daratumumab and elotuzumab for the treatment of relapsed refractory multiple myeloma (RRMM).

Data sources

A literature search of MEDLINE, PubMed, the US National Institutes of Health Clinicaltrials.gov, the Food and Drug administration, and relevant meeting abstracts was conducted using the terms daratumumab, elotuzumab, multiple myeloma, anti-CD38, HuMax-CD38, HuLuc63, SLAMF7, and anti-CS1 STUDY SELECTION/DATA EXTRACTION: Human and animal studies describing the pharmacology, pharmacokinetics, efficacy, and safety of daratumumab and elotuzumab for MM were identified.

Data synthesis

Daratumumab (anti-CD38) and elotuzumab (anti-CS1) have been recently FDA approved for the treatment of RRMM after show

SUBMITTER: Afifi S 

PROVIDER: S-EPMC5533303 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature